首页 > 最新文献

Experimental oncology最新文献

英文 中文
PROSTATE CANCER DIAGNOSTICS MODELING USING THE INFRARED IMAGING METHOD.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.268
B Partsvania, T Sulaberidze, A Khuskivadze, S Abazadze

Background: Imaging plays an important role in the identification of prostate cancer (PCa). However, a shortcoming of the current imaging techniques is their inability to detect PCa at an early stage of development when tumor volume is small. This led us to explore new and improved imaging methods. The phenomenon that infrared (IR) light penetrates biological tissues caused our efforts to utilize IR rays for PCa visualization. The aim of this study was to conduct model experiments to demonstrate how IR light could be used in the future to detect PCa in vivo.

Materials and methods: Experiments were carried out on prostates obtained after radical prostatectomy. The study was approved by the ethical commission of the Georgia-Israel Joint Clinic "Gidmedi". We developed a device that uses IR light to illuminate a prostate from the inside. In order to get IR images of the prostate, we developed a device with an IR-sensitive charge-coupled device (CCD) camera. The model experiments showed that the intensity of IR light passing through noncancerous and malignant prostate tissues is significantly different allowing their distinguishment. The visualization device can detect PCa lesions as small as several millimeters.

Conclusion: These results suggest that our device could be useful for the detection of small PCa lesions.

{"title":"PROSTATE CANCER DIAGNOSTICS MODELING USING THE INFRARED IMAGING METHOD.","authors":"B Partsvania, T Sulaberidze, A Khuskivadze, S Abazadze","doi":"10.15407/exp-oncology.2024.03.268","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.268","url":null,"abstract":"<p><strong>Background: </strong>Imaging plays an important role in the identification of prostate cancer (PCa). However, a shortcoming of the current imaging techniques is their inability to detect PCa at an early stage of development when tumor volume is small. This led us to explore new and improved imaging methods. The phenomenon that infrared (IR) light penetrates biological tissues caused our efforts to utilize IR rays for PCa visualization. The aim of this study was to conduct model experiments to demonstrate how IR light could be used in the future to detect PCa in vivo.</p><p><strong>Materials and methods: </strong>Experiments were carried out on prostates obtained after radical prostatectomy. The study was approved by the ethical commission of the Georgia-Israel Joint Clinic \"Gidmedi\". We developed a device that uses IR light to illuminate a prostate from the inside. In order to get IR images of the prostate, we developed a device with an IR-sensitive charge-coupled device (CCD) camera. The model experiments showed that the intensity of IR light passing through noncancerous and malignant prostate tissues is significantly different allowing their distinguishment. The visualization device can detect PCa lesions as small as several millimeters.</p><p><strong>Conclusion: </strong>These results suggest that our device could be useful for the detection of small PCa lesions.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"268-272"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDENTIFICATION OF CLINICALLY RELEVANT GENE VARIANTS IN COLON ADENOCARCINOMA SAMPLES OF UKRAINIAN PATIENTS USING A COMPREHENSIVE CANCER PANEL: A PILOT STUDY.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.221
G Gerashchenko, R Gulkovskyi, N Melnichuk, N Hryshchenko, T Marchyshak, O Mankovska, A Bezverkhiy, I Kotuza, L Rosha, A Kotuza, Z Tkachuk, V Kashuba, M Tukalo

The study aimed to identify the clinically relevant gene variants in colon adenocarcinoma samples of Ukrainian patients using the NGS Comprehensive Cancer Panel (CCP) to implement them conveniently in clinical practice.

Methods: We have studied 20 samples of Ukrainian patients with colorectal adenocarcinomas of various differentiation grades. To identify the clinically relevant gene variants, the CCP data were filtered using the Franklin by Genoox database.

Results: A total of 79 clinically relevant gene variant alterations (SNVs, INDELs) were found in 28 of 409 genes. The largest number of mutations was found in 3 genes, APC, TP53, and KRAS (16, 14, and 8, accordingly). We revealed 4 variants in PTEN and SMAD4, 3 variants in CHEK2, ERBB2, and PIK3CA genes, and 2 variants in AKT1, ATM, DST, IDH1, and TCF12. Mutations for 7 genes, KRAS, TP53, CHEK2, PTEN, AKT1, APC, and SMAD4, were found in more than 1 tumor tissue sample. Tier 1-2 gene variants rate was about 50% of all genetic variants. The therapeutic significance was found in more than 55% of mutations. Additionally, 11 novel genetic mutations in 9 genes have been identified, including G6PD, APC, DST, SINE1, SMAD2, and FLCN.

Conclusions: These data suggest a high level of clinical relevance of the NGS CCP approach. Further confirmation on a larger number of samples and using a deeper analysis by other approaches is required.

{"title":"IDENTIFICATION OF CLINICALLY RELEVANT GENE VARIANTS IN COLON ADENOCARCINOMA SAMPLES OF UKRAINIAN PATIENTS USING A COMPREHENSIVE CANCER PANEL: A PILOT STUDY.","authors":"G Gerashchenko, R Gulkovskyi, N Melnichuk, N Hryshchenko, T Marchyshak, O Mankovska, A Bezverkhiy, I Kotuza, L Rosha, A Kotuza, Z Tkachuk, V Kashuba, M Tukalo","doi":"10.15407/exp-oncology.2024.03.221","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.221","url":null,"abstract":"<p><p>The study aimed to identify the clinically relevant gene variants in colon adenocarcinoma samples of Ukrainian patients using the NGS Comprehensive Cancer Panel (CCP) to implement them conveniently in clinical practice.</p><p><strong>Methods: </strong>We have studied 20 samples of Ukrainian patients with colorectal adenocarcinomas of various differentiation grades. To identify the clinically relevant gene variants, the CCP data were filtered using the Franklin by Genoox database.</p><p><strong>Results: </strong>A total of 79 clinically relevant gene variant alterations (SNVs, INDELs) were found in 28 of 409 genes. The largest number of mutations was found in 3 genes, APC, TP53, and KRAS (16, 14, and 8, accordingly). We revealed 4 variants in PTEN and SMAD4, 3 variants in CHEK2, ERBB2, and PIK3CA genes, and 2 variants in AKT1, ATM, DST, IDH1, and TCF12. Mutations for 7 genes, KRAS, TP53, CHEK2, PTEN, AKT1, APC, and SMAD4, were found in more than 1 tumor tissue sample. Tier 1-2 gene variants rate was about 50% of all genetic variants. The therapeutic significance was found in more than 55% of mutations. Additionally, 11 novel genetic mutations in 9 genes have been identified, including G6PD, APC, DST, SINE1, SMAD2, and FLCN.</p><p><strong>Conclusions: </strong>These data suggest a high level of clinical relevance of the NGS CCP approach. Further confirmation on a larger number of samples and using a deeper analysis by other approaches is required.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"221-227"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SIGNIFICANCE OF miRNA-185-5P AND miRNA-424-5P AS PROGNOSTIC MARKERS IN PROGRESSION OF EARLY-STAGE ENDOMETRIAL CANCER. miRNA-185-5P和miRNA-424-5P在早期晚期肿瘤进展过程中作为预后标志物的意义。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.244
N P Iurchenko, N M Glushchenko, S V Nespryadko, L G Buchynska

Aim: To compare the expression of miRNA-185-5p and miRNA-424-5p in tumor cells and peripheral blood serum (PBS) of patients with endometrioid carcinoma of the endometrium (ECE) and to evaluate the significance of these biomarkers in cancer progression.

Materials and methods: The study was conducted on the samples of peripheral blood serum (PBS) and tumor tissue of 58 patients with stage I ECE using clinical and morphological methods and real-time polymerase chain reaction.

Results: A significant increase in the levels of circulating and tumor-associated miRNA-424-5p was established in ECE patients with a history of recurrences compared to patients without recurrences. To the contrary, the expression level of miRNA-185-5p increased in the PBS and decreased in the tumor tissue of ECE patients with recurrences compared to the patients without recurrence. In addition, we revealed that the expression levels of the studied miRNAs were associated with the differentiation grade and degree of tumor invasion. We established that miRNA-424-5p levels in PBS could serve as the most significant indicator for predicting the occurrence of recurrence in patients with ECE (AUC = 0.991; Sp 94.0%; Se 99.9%).

Conclusions: The expression features of miRNA-185-5p and miRNA-424-5p in the PBS and tumor tissue of patients with ECE are associated with the aggressiveness of cancer course and the risk of recurrence.

{"title":"SIGNIFICANCE OF miRNA-185-5P AND miRNA-424-5P AS PROGNOSTIC MARKERS IN PROGRESSION OF EARLY-STAGE ENDOMETRIAL CANCER.","authors":"N P Iurchenko, N M Glushchenko, S V Nespryadko, L G Buchynska","doi":"10.15407/exp-oncology.2024.03.244","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.244","url":null,"abstract":"<p><strong>Aim: </strong>To compare the expression of miRNA-185-5p and miRNA-424-5p in tumor cells and peripheral blood serum (PBS) of patients with endometrioid carcinoma of the endometrium (ECE) and to evaluate the significance of these biomarkers in cancer progression.</p><p><strong>Materials and methods: </strong>The study was conducted on the samples of peripheral blood serum (PBS) and tumor tissue of 58 patients with stage I ECE using clinical and morphological methods and real-time polymerase chain reaction.</p><p><strong>Results: </strong>A significant increase in the levels of circulating and tumor-associated miRNA-424-5p was established in ECE patients with a history of recurrences compared to patients without recurrences. To the contrary, the expression level of miRNA-185-5p increased in the PBS and decreased in the tumor tissue of ECE patients with recurrences compared to the patients without recurrence. In addition, we revealed that the expression levels of the studied miRNAs were associated with the differentiation grade and degree of tumor invasion. We established that miRNA-424-5p levels in PBS could serve as the most significant indicator for predicting the occurrence of recurrence in patients with ECE (AUC = 0.991; Sp 94.0%; Se 99.9%).</p><p><strong>Conclusions: </strong>The expression features of miRNA-185-5p and miRNA-424-5p in the PBS and tumor tissue of patients with ECE are associated with the aggressiveness of cancer course and the risk of recurrence.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"244-252"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA. 适形放疗联合放射调节剂对头颈部鳞状细胞癌患者血清中 VEGF、COX-2 和 PGE-2 含量的影响。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.253
N Mitryayeva, L Grebinyk, S Artiukh, N Bilozor, V Starenkiy

Background: The development of new approaches to modeling tumor radiosensitivity in patients with head and neck squamous cell carcinoma (HNSCC) is an important problem for overcoming tumor radioresistance. New agents for radiomodification are inhibitors of the enzyme cyclooxygenase-2 (COX-2). The study of markers of radioresistance in cancer patients undergoing radiotherapy (RT) in combination with COX-2 inhibitors and chemotherapy may contribute to the effectiveness of RT.

Aim: To determine the effect of conformal RT in combination with radiomodifiers (celecoxib, cisplatin, or their combination) on the content of vascular endothelial growth factor (VEGF), COX-2, and prostaglandin E-2 (PGE-2) in the serum of patients with HNSCC.

Materials and methods: 47 patients with HNSCC were divided into 4 groups: RT in combination with celecoxib and cisplatin, RT with cisplatin, RT with celecoxib, and RT. Patients received radiation treatment on a Clinac 600C linear accelerator. The levels of VEGF, COX-2, and PGE-2 in the serum were determined by enzyme immunoassay.

Results: Blocking COX-2 in patients with HNSCC leads to a decrease in VEGF levels. The largest decrease in VEGF levels was observed in a group treated by RT in combination with celecoxib and cisplatin, indicating a more effective antiangiogenic effect. The changes in the levels of VEGF, COX-2, and PGE-2, which are most pronounced under the combined effect of RT and both radiomodifiers, coincided with an objective response to radiation treatment.

Conclusions: The data obtained indicate the effect of radiomodification on the suppression of angiogenesis, which is most pronounced under the combined effect of RT and both radiomodifiers. The decrease in the levels of PGE- 2, COX-2, and VEGF coincides with the clinical efficacy of radiotherapy according to RECIST 1.1 criteria.

{"title":"INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA.","authors":"N Mitryayeva, L Grebinyk, S Artiukh, N Bilozor, V Starenkiy","doi":"10.15407/exp-oncology.2024.03.253","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.253","url":null,"abstract":"<p><strong>Background: </strong>The development of new approaches to modeling tumor radiosensitivity in patients with head and neck squamous cell carcinoma (HNSCC) is an important problem for overcoming tumor radioresistance. New agents for radiomodification are inhibitors of the enzyme cyclooxygenase-2 (COX-2). The study of markers of radioresistance in cancer patients undergoing radiotherapy (RT) in combination with COX-2 inhibitors and chemotherapy may contribute to the effectiveness of RT.</p><p><strong>Aim: </strong>To determine the effect of conformal RT in combination with radiomodifiers (celecoxib, cisplatin, or their combination) on the content of vascular endothelial growth factor (VEGF), COX-2, and prostaglandin E-2 (PGE-2) in the serum of patients with HNSCC.</p><p><strong>Materials and methods: </strong>47 patients with HNSCC were divided into 4 groups: RT in combination with celecoxib and cisplatin, RT with cisplatin, RT with celecoxib, and RT. Patients received radiation treatment on a Clinac 600C linear accelerator. The levels of VEGF, COX-2, and PGE-2 in the serum were determined by enzyme immunoassay.</p><p><strong>Results: </strong>Blocking COX-2 in patients with HNSCC leads to a decrease in VEGF levels. The largest decrease in VEGF levels was observed in a group treated by RT in combination with celecoxib and cisplatin, indicating a more effective antiangiogenic effect. The changes in the levels of VEGF, COX-2, and PGE-2, which are most pronounced under the combined effect of RT and both radiomodifiers, coincided with an objective response to radiation treatment.</p><p><strong>Conclusions: </strong>The data obtained indicate the effect of radiomodification on the suppression of angiogenesis, which is most pronounced under the combined effect of RT and both radiomodifiers. The decrease in the levels of PGE- 2, COX-2, and VEGF coincides with the clinical efficacy of radiotherapy according to RECIST 1.1 criteria.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"253-259"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AGGRESSIVE RHABDOID TUMOR IN THE RIGHT LUNG: A CASE REPORT.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.273
O Dyadyk, C Shatrova, V Ilchenko, L Rosha, V Zaritska, I Irkin, Yu Beketova, P Snisarevskyi

Rhabdoid tumor is a rare and aggressive neoplasm that usually occurs in children and is often localized in the central nervous system and kidneys, but can be found in many other sites. In our case report, we describe a tumor that was found on computed tomography in the thoracic region of a 62-year-old male and was successfully surgically resected. The images and descriptions of our findings and the results of the additional immunohistochemical studies allow us to make the final diagnosis.

{"title":"AGGRESSIVE RHABDOID TUMOR IN THE RIGHT LUNG: A CASE REPORT.","authors":"O Dyadyk, C Shatrova, V Ilchenko, L Rosha, V Zaritska, I Irkin, Yu Beketova, P Snisarevskyi","doi":"10.15407/exp-oncology.2024.03.273","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.273","url":null,"abstract":"<p><p>Rhabdoid tumor is a rare and aggressive neoplasm that usually occurs in children and is often localized in the central nervous system and kidneys, but can be found in many other sites. In our case report, we describe a tumor that was found on computed tomography in the thoracic region of a 62-year-old male and was successfully surgically resected. The images and descriptions of our findings and the results of the additional immunohistochemical studies allow us to make the final diagnosis.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"273-277"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ROLE OF RIBONUCLEASES IN THE REGULATION OF IMMUNE RESPONSE.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.192
V Shlyakhovenko, O Samoylenko, A Verbinenko, I Ganusevich

Ribonucleases (RNases) perform many different functions in living systems. They are responsible for the formation and processing of various ribonucleic acids (RNAs), including the messenger RNA and all types of microRNAs, and determine the duration of the existence of different RNAs in the cell and extracellular environment. RNases are ubiquitously expressed in many tissue types. This short review discusses the major types and main functions of RNases, their homeostatic functions, influence of transcription, immunomodulation, and the role of extracellular RNases in the immune defense mechanisms.

核糖核酸酶(RNases)在生命系统中发挥着多种不同的功能。它们负责形成和处理各种核糖核酸(RNA),包括信使 RNA 和所有类型的 microRNA,并决定不同 RNA 在细胞和细胞外环境中的存在时间。RNase 在许多组织类型中普遍表达。这篇简短的综述将讨论 RNases 的主要类型和主要功能、它们的平衡功能、对转录的影响、免疫调节以及细胞外 RNases 在免疫防御机制中的作用。
{"title":"ROLE OF RIBONUCLEASES IN THE REGULATION OF IMMUNE RESPONSE.","authors":"V Shlyakhovenko, O Samoylenko, A Verbinenko, I Ganusevich","doi":"10.15407/exp-oncology.2024.03.192","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.192","url":null,"abstract":"<p><p>Ribonucleases (RNases) perform many different functions in living systems. They are responsible for the formation and processing of various ribonucleic acids (RNAs), including the messenger RNA and all types of microRNAs, and determine the duration of the existence of different RNAs in the cell and extracellular environment. RNases are ubiquitously expressed in many tissue types. This short review discusses the major types and main functions of RNases, their homeostatic functions, influence of transcription, immunomodulation, and the role of extracellular RNases in the immune defense mechanisms.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"192-201"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EVOLUTION OF METFORMIN IN BREAST CANCER THERAPY IN LAST TWO DECADES: A REVIEW.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.185
R Sarathi, S Sarumathy, V M Durai Mavalavan

Among women, breast cancer is one of the most prevalent cancers. The disease has a complex etiology, with multiple biological pathways contributing to its development. As insulin signaling has mitogenic effects, glucose is a necessary cellular metabolic substrate, and the growth and metastasis of breast cancer are closely related to cellular glucose metabolism. Anti-diabetic medications have drawn increased attention as a potential treatment for breast cancer. Metformin lowers cancer incidence and death rates in patients with type 2 diabetes, according to epidemiologic studies. Preclinical studies conducted in vivo and in vitro offer fascinating new insights into the cellular mechanisms underlying metformin oncostatic action. We present an overview of the mechanisms of anticancer effects of metformin and discuss its potential function as an adjuvant in the treatment of breast cancer.

{"title":"EVOLUTION OF METFORMIN IN BREAST CANCER THERAPY IN LAST TWO DECADES: A REVIEW.","authors":"R Sarathi, S Sarumathy, V M Durai Mavalavan","doi":"10.15407/exp-oncology.2024.03.185","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.185","url":null,"abstract":"<p><p>Among women, breast cancer is one of the most prevalent cancers. The disease has a complex etiology, with multiple biological pathways contributing to its development. As insulin signaling has mitogenic effects, glucose is a necessary cellular metabolic substrate, and the growth and metastasis of breast cancer are closely related to cellular glucose metabolism. Anti-diabetic medications have drawn increased attention as a potential treatment for breast cancer. Metformin lowers cancer incidence and death rates in patients with type 2 diabetes, according to epidemiologic studies. Preclinical studies conducted in vivo and in vitro offer fascinating new insights into the cellular mechanisms underlying metformin oncostatic action. We present an overview of the mechanisms of anticancer effects of metformin and discuss its potential function as an adjuvant in the treatment of breast cancer.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"185-191"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.260
A M Rudzite, D Auzina, S Lejniece

Background: Patients with hematological malignancies (HM) are considered to have a high risk of developing severe and life-threatening infections including COVID-19 because of immune deficiency and immunosuppressive treatments. Although the COVID pandemic spread worldwide, morbidity and mortality data varied from country to country. A more accurate identification of risk factors would allow the improvement of the clinical management of HM patients.

Aim: This study aimed to determine real-life data - the mortality rate, clinical outcomes, and risk factors affecting mortality in patients with HM and COVID-19 at the Riga East University Hospital (REUH) in Latvia.

Materials and methods: In this retrospective non-interventional cohort study, we included adult patients treated in REUH with ongoing HM and laboratory- confirmed COVID-19 observed between December 1st, 2020, and March 31st, 2023. All data were analyzed using descriptive statistics, binary logistic regression, univariable Cox regression model, and other methods.

Results: We registered 156 patients with 11 different HMs. Multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia were the most common HM. COVID-19 mortality rate was 19.9% (31/156). Factors increasing the risk of death included the severity of COVID-19 (p < 0.001), the accession of bacterial infection (p < 0.001), longer hospital stay (p = 0.037), absolute neutrophil count (ANC) ≤ 0.5 × 109/mm3 (p = 0.014), fever (p = 0.039), and acute myeloid leukemia (p = 0.002). We also confirmed that the mortality in the third pandemic wave was significantly lower than in the second wave (p = 0.002). Although vaccination seemed to be a risk-mitigating factor (58.8% [10/17] of those who died from COVID-19 were not vaccinated), no statistically important correlation was found (p = 0.690).

Conclusion: This survey confirmed that the COVID-19 mortality rate was higher in patients with HM (19.9% [31/156]) than in the population. ANC, severity of COVID-19, accession of bacterial infection, hospital stay, fever, and acute myeloid leukemia were the factors that increased mortality in HM patients.

{"title":"FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES.","authors":"A M Rudzite, D Auzina, S Lejniece","doi":"10.15407/exp-oncology.2024.03.260","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.260","url":null,"abstract":"<p><strong>Background: </strong>Patients with hematological malignancies (HM) are considered to have a high risk of developing severe and life-threatening infections including COVID-19 because of immune deficiency and immunosuppressive treatments. Although the COVID pandemic spread worldwide, morbidity and mortality data varied from country to country. A more accurate identification of risk factors would allow the improvement of the clinical management of HM patients.</p><p><strong>Aim: </strong>This study aimed to determine real-life data - the mortality rate, clinical outcomes, and risk factors affecting mortality in patients with HM and COVID-19 at the Riga East University Hospital (REUH) in Latvia.</p><p><strong>Materials and methods: </strong>In this retrospective non-interventional cohort study, we included adult patients treated in REUH with ongoing HM and laboratory- confirmed COVID-19 observed between December 1st, 2020, and March 31st, 2023. All data were analyzed using descriptive statistics, binary logistic regression, univariable Cox regression model, and other methods.</p><p><strong>Results: </strong>We registered 156 patients with 11 different HMs. Multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia were the most common HM. COVID-19 mortality rate was 19.9% (31/156). Factors increasing the risk of death included the severity of COVID-19 (p < 0.001), the accession of bacterial infection (p < 0.001), longer hospital stay (p = 0.037), absolute neutrophil count (ANC) ≤ 0.5 × 109/mm3 (p = 0.014), fever (p = 0.039), and acute myeloid leukemia (p = 0.002). We also confirmed that the mortality in the third pandemic wave was significantly lower than in the second wave (p = 0.002). Although vaccination seemed to be a risk-mitigating factor (58.8% [10/17] of those who died from COVID-19 were not vaccinated), no statistically important correlation was found (p = 0.690).</p><p><strong>Conclusion: </strong>This survey confirmed that the COVID-19 mortality rate was higher in patients with HM (19.9% [31/156]) than in the population. ANC, severity of COVID-19, accession of bacterial infection, hospital stay, fever, and acute myeloid leukemia were the factors that increased mortality in HM patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"260-267"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EFFECT OF ADHESIVE LLC CELL PRETREATMENT BY OXAMATE ON THE SURVIVAL INDEXES AFTER TRANSITION TO DE-ADHESIVE GROWTH. 草氨酸盐预处理粘附性 llc 细胞对过渡到非粘附性生长后存活指标的影响。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.237
Yu Stepanov, D Kolesnik, Yu Yakshibaeva, G Solyanik

Background: The ability to metabolic reprogramming is a distinctive feature of metastatically active tumor cells. A classic example of metabolic reprogramming, characteristic of almost all malignant cells, is aerobic glycolysis. Therefore, inhibition of glycolysis in tumor cells is considered a promising strategy for antitumor therapy.

Aim: To generate Lewis lung carcinoma (LLC) cell subpopulation after pretreatment by a lactate dehydrogenase (LDH) inhibitor - oxamate in adhesive growth conditions, and then to study the metabolism of this subpopulation in the anchorage-independent growth conditions.

Materials and methods: LLC cells were cultured without oxamate or with 17 mM oxamate in the adhesive growth conditions with the following transition to the anchorage-independent growth conditions without oxamate. A distribution of LLC cells by cell cycle phases, apoptosis rate, levels of reactive oxygen species (ROS), E-cadherin, and vimentin were determined by flow cytometry. Glucose consumption and lactate production were determined by spectrophotometry.

Results: 48-h oxamate treatment in adhesive growth conditions resulted in a 30% decrease of the total number of LLC cells compared to the control. In 72 h after the transfer of both oxamate-treated and control cells into the anchorage-independent growth condition without oxamate, the number of viable cells pretreated with oxamate was reduced by 17% (p < 0.05) compared to the control cells. However, the distribution of cells by cell cycle phases did not differ. In cells pre-treated with oxamate, the rate of glucose consumption decreased by 20% (p < 0.05), ROS generation was reduced by 17%, vimentin expression decreased by 10% while the rate of lactate production was the same in oxamate-pretreated and control cells.

Conclusion: The cytostatic effect of oxamate demonstrated in adhesive growth conditions persisted for 72 h in the anchorage-independent growth conditions. The absence of differences in the cell cycle phase distribution and a decrease in the ROS generation may indicate the initial stage of overcoming the cytostatic effect of oxamate after 72 h of culturing LLC cells in anchorage- independent growth conditions.

{"title":"EFFECT OF ADHESIVE LLC CELL PRETREATMENT BY OXAMATE ON THE SURVIVAL INDEXES AFTER TRANSITION TO DE-ADHESIVE GROWTH.","authors":"Yu Stepanov, D Kolesnik, Yu Yakshibaeva, G Solyanik","doi":"10.15407/exp-oncology.2024.03.237","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.237","url":null,"abstract":"<p><strong>Background: </strong>The ability to metabolic reprogramming is a distinctive feature of metastatically active tumor cells. A classic example of metabolic reprogramming, characteristic of almost all malignant cells, is aerobic glycolysis. Therefore, inhibition of glycolysis in tumor cells is considered a promising strategy for antitumor therapy.</p><p><strong>Aim: </strong>To generate Lewis lung carcinoma (LLC) cell subpopulation after pretreatment by a lactate dehydrogenase (LDH) inhibitor - oxamate in adhesive growth conditions, and then to study the metabolism of this subpopulation in the anchorage-independent growth conditions.</p><p><strong>Materials and methods: </strong>LLC cells were cultured without oxamate or with 17 mM oxamate in the adhesive growth conditions with the following transition to the anchorage-independent growth conditions without oxamate. A distribution of LLC cells by cell cycle phases, apoptosis rate, levels of reactive oxygen species (ROS), E-cadherin, and vimentin were determined by flow cytometry. Glucose consumption and lactate production were determined by spectrophotometry.</p><p><strong>Results: </strong>48-h oxamate treatment in adhesive growth conditions resulted in a 30% decrease of the total number of LLC cells compared to the control. In 72 h after the transfer of both oxamate-treated and control cells into the anchorage-independent growth condition without oxamate, the number of viable cells pretreated with oxamate was reduced by 17% (p < 0.05) compared to the control cells. However, the distribution of cells by cell cycle phases did not differ. In cells pre-treated with oxamate, the rate of glucose consumption decreased by 20% (p < 0.05), ROS generation was reduced by 17%, vimentin expression decreased by 10% while the rate of lactate production was the same in oxamate-pretreated and control cells.</p><p><strong>Conclusion: </strong>The cytostatic effect of oxamate demonstrated in adhesive growth conditions persisted for 72 h in the anchorage-independent growth conditions. The absence of differences in the cell cycle phase distribution and a decrease in the ROS generation may indicate the initial stage of overcoming the cytostatic effect of oxamate after 72 h of culturing LLC cells in anchorage- independent growth conditions.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"237-243"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
THE INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND LECTIN OF B. SUBTILIS IMV B-7724 ON THE ANTITUMOR IMMUNE RESPONSE OF MICE WITH EHRLICH ADENOCARCINOMA.
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.228
N Fedosova, N Cheremshenko, S Gogol, N Bezdieniezhnykh, V Tikhonov, I Voyeykova, V Konovalenko, V Chekhun

Aim: To investigate the effect of bacteria of the genus Bifidobacterium and the extracellular metabolite of B. subtilis IMV B-7724 on the antitumor immune response of mice with a model tumor.

Materials and methods: The study was conducted on Balb/c mice with transplanted solid Ehrlich adenocarcinoma (ACE). Starting from the 2nd day after the transplantation of tumor cells, the animals of the experimental groups were treated with lectin of B. subtilis IMV B-7724 (s/c, 1 mg/kg of weight), Bifidobacterium animalis (per os, 7 × 105 CFU/mouse) or their combination. The immunological studies were performed on the 21st and 28th days of tumor growth. The functional activity of natural killer cells (NK), cytotoxic T-lymphocytes (CTL), as well as the ability of lymphocytes from the peripheral lymph nodes (PLN) to transform into blast cells under the influence of T- (Con A) and B-cell (LPS) mitogens were determined.

Results: Administration of probiotic components to the mice with ACE led to the activation of innate immune responses, that is, to a significant increase in the cytotoxic activity of NK, especially in the case of their combined use. The NK cytotoxicity index was higher than that in the non-treated ACE-bearing mice and the intact control by 3.7 and 2.1 times, respectively (p < 0.05). Similarly, the highest specific cytotoxic activity of spleen lymphocytes was observed upon the combined use of the microbial preparations: the CTL cytotoxicity index was nearly 2.5-fold higher than in the non-treated ACE-bearing mice. The data on the ability of PLN lymphocytes to transform into blast cells under the influence of Con A and LPS indicated the preservation of the functional activity of lymphocytes in the animals of the experimental groups during ACE growth.

Conclusion: Both B. animalis and lectin of B. subtilis IMV B-7724 have a significant influence on the effectors of the natural and adaptive immunity of mice with ACE. Their combined use was found to be the most effective.

{"title":"THE INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND LECTIN OF B. SUBTILIS IMV B-7724 ON THE ANTITUMOR IMMUNE RESPONSE OF MICE WITH EHRLICH ADENOCARCINOMA.","authors":"N Fedosova, N Cheremshenko, S Gogol, N Bezdieniezhnykh, V Tikhonov, I Voyeykova, V Konovalenko, V Chekhun","doi":"10.15407/exp-oncology.2024.03.228","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.228","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the effect of bacteria of the genus Bifidobacterium and the extracellular metabolite of B. subtilis IMV B-7724 on the antitumor immune response of mice with a model tumor.</p><p><strong>Materials and methods: </strong>The study was conducted on Balb/c mice with transplanted solid Ehrlich adenocarcinoma (ACE). Starting from the 2nd day after the transplantation of tumor cells, the animals of the experimental groups were treated with lectin of B. subtilis IMV B-7724 (s/c, 1 mg/kg of weight), Bifidobacterium animalis (per os, 7 × 105 CFU/mouse) or their combination. The immunological studies were performed on the 21st and 28th days of tumor growth. The functional activity of natural killer cells (NK), cytotoxic T-lymphocytes (CTL), as well as the ability of lymphocytes from the peripheral lymph nodes (PLN) to transform into blast cells under the influence of T- (Con A) and B-cell (LPS) mitogens were determined.</p><p><strong>Results: </strong>Administration of probiotic components to the mice with ACE led to the activation of innate immune responses, that is, to a significant increase in the cytotoxic activity of NK, especially in the case of their combined use. The NK cytotoxicity index was higher than that in the non-treated ACE-bearing mice and the intact control by 3.7 and 2.1 times, respectively (p < 0.05). Similarly, the highest specific cytotoxic activity of spleen lymphocytes was observed upon the combined use of the microbial preparations: the CTL cytotoxicity index was nearly 2.5-fold higher than in the non-treated ACE-bearing mice. The data on the ability of PLN lymphocytes to transform into blast cells under the influence of Con A and LPS indicated the preservation of the functional activity of lymphocytes in the animals of the experimental groups during ACE growth.</p><p><strong>Conclusion: </strong>Both B. animalis and lectin of B. subtilis IMV B-7724 have a significant influence on the effectors of the natural and adaptive immunity of mice with ACE. Their combined use was found to be the most effective.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"228-236"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1